Buy Medetomidine (anesthetic) Cas 86347-14-0
Medetomidine is a veterinary anesthetic medication with potent sedative effects. As of December 2025, it is an emerging illicit drug adulterant.[4][5]
It is a racemic mixture of two stereoisomers, levomedetomidine and dexmedetomidine, the latter being the isomer with the pharmacologic effect as an alpha 2- adrenergic agonist. Effects can be reversed using atipamezole.
It was developed by Orion Pharma.[6] It is approved for dogs in the United States, and distributed in the United States by Pfizer Animal Health and by Novartis Animal Health in Canada under the product name Domitor. Starting in 2022 medetomidine has been detected in the US in samples of illicit drugs and associated with overdoses.
The free base form of medetomidine is sold as an antifouling substance for marine paints.[7]
History
Medetomidine was developed in 1987 for use as a sedative in veterinary medicine in Europe. In 1996 medetomidine received FDA approval for use in dogs.[4]
Pharmacology
Medetomidine is a racemic mixture of two optical or stereoisomers, levomedetomidine and dexmedetomidine.[8] The latter causes the alpha 2- adrenergic agonist effects.[9]
Medetomidine is an α2-adrenergic receptor agonist that binds at a ratio of 1620:1 with imidazoline receptor activity.[10]
Medetomidine is metabolised in the liver via hydroxylation.[10]
Reviews
There are no reviews yet.